None listed
Conditions
Brief summary
This study aims (1) to define the atherosclerotic plaque characteristics, inflammation and microvascular physiology in patients with acute coronary syndromes; (2) to evaluate the impacts of colchicine on atherosclerotic plaques, inflammation and microvascular physiology in ACS; and (3) to correlate plaque morphology and coronary physiology with future cardiac events
Interventions
Participants will be receiving a STAT oral dose of colchicine 6 to 24 hours prior to the percutaneous coronary intervention procedure. The STAT dose is given as 1mg followed 1 hour later by 0.5mg of colchicine: Three tablets in total.
Sponsors
St. Vincent's Hospital Melbourne
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Patients admitted with acute coronary syndromes Multivessel disease on coronary angiography with plan for staged PCI
Exclusion criteria
Severe hepatic and renal impairment Patients who are intolerant of colchicine Pre-existing colchicine use for other medical conditions Concurrent administration of immunosuppressant therapy Known active malignancy Pregnancy or lactating women
Outcome results
None listed